Please login to the form below

Procoralan

This page shows the latest Procoralan news and features for those working in and with pharma, biotech and healthcare.

The drug has been marketed for years in Europe by privately-held Servier under the Procoralan brand name.

FDA clears Amgen's Corlaner for heart failure

Corlaner is already on the market in Europe - where it is sold by privately held Servier as Procoralan and was approved to treat stable angina in 2005 and CHF in 2012.
Amgen gets priority review for chronic heart failure hope

require additional clinical trials, despite the fact that the drug is already sold (as Servier's Procoralan) for CHF and also stable angina in Europe.
Amgen throws its hat into the cholesterol antibody ring

Procoralan (ivabradine) from Servier in July.
Amgen drug misses endpoint in acute heart failure trial

This was part of a deal that involved Amgen obtaining US rights to Servier's chronic heart failure drug Procoralan (ivabradine).
Amgen buys US rights to Servier’s Procoralan

Amgen buys US rights to Servier’ s Procoralan. Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe. ... The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Heart failure therapy embarks on a new era

has been sold for HF in Europe as Procoralan/Corlenter by originator Servier since 2012.
Deal Watch table for July 2013

100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2).
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Amgen is paying $50m upfront for US rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Add my company

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...